Evaluation of the Clinical Safety and Efficacy of the 34/38 mm Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Subjects According to the Indication for Use
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Zotarolimus (Primary)
- Indications Arteriosclerosis; Cardiovascular disorders; Coronary artery disease; Ischaemic heart disorders
- Focus Therapeutic Use
- 02 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Apr 2017 New trial record
- 19 Apr 2017 Status has been changed from not yet recruiting to recruiting.